EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...
Pharmabiz12h
EMA committee recommends marketing approval for AbbVie’s mirvetuximab soravtansine for the treatment of certain adult ovarian cancer
North Chicago, Illinois Monday, September 23, 2024, 13:00 Hrs [IST] ...
Medscape3d
EMA Backs Approval of Elahere for Ovarian Cancer
Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ...
AbbVie: CHMP Adopts Positive Opinion For Mirvetuximab Soravtansine - Quick Facts
AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion ...
Abbvie Slides on ELAHERE Opinion of its Cancer Treatment
AbbVie (NYSE: ABBV) shares lost ground Friday. The company announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...
AbbVie Gets CHMP Backing for Elahere in Ovarian Cancer
Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...
clinicaltrialsarena4d
Starton successfully delivers cancer drug using on-body injector
Starton is planning larger Phase II trials for chronic lymphocytic leukaemia (CLL) and multiple myeloma in 2025. Credit: Ground Picture via Shutterstock. Starton Therapeutics has successfully ...
clinicaltrialsarena5d
Daiichi Sankyo and MSD’s ADC improves progression-free survival in NSCLC trial
Patritumab deruxtecan’s safety profile in the trial was in line with previous lung cancer studies. Credit: Jo Panuwat D/Shutterstock. Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase ...